Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer (POWER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01627379 |
Recruitment Status :
Terminated
(Sponsor decision due to recommendation of the IDMC.)
First Posted : June 25, 2012
Last Update Posted : March 2, 2018
|
Sponsor:
AIO-Studien-gGmbH
Collaborators:
Amgen
Assign Data Management and Biostatistics GmbH
Assign Clinical Research GmbH
Information provided by (Responsible Party):
AIO-Studien-gGmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Terminated |
---|---|
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | May 2017 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):